155488-25-8
Chemical Structure
Sograzepide
Synonym(s): Netazepide; YF 476; YM-220
- CAS No.: 155488-25-8
- Formula:C28H30N6O3
- Molecular Weight:498.58
IUPAC Name: (R)-1-(1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-(methylamino)phenyl)urea
InChIKey: YDZYKNJZCVIKPP-VWLOTQADSA-N
SMILES: O=C(NC1=CC=CC(NC)=C1)N[C@H]2C(N(CC(C(C)(C)C)=O)C3=CC=CC=C3C(C4=NC=CC=C4)=N2)=O
Biological Activity: Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM[1]. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sograzepide | 98.04% | Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM. Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-U00360R(Rac)-Sograzepide (Standard) -
Similarity Score 0.92
HY-129357CCK-B Receptor Antagonist 2 -
Similarity Score 0.88
HY-109028Ceclazepide -
Similarity Score 0.62
HY-103355RYM022 (Standard) -
Similarity Score 0.62
HY-106840RL-365260 (Standard) -
Similarity Score 0.61
HY-120862L 368935 -
Similarity Score 0.61
HY-184207Zinc13732787 -
Similarity Score 0.59
HY-176048ChEMBL22003 -
Similarity Score 0.56
HY-14176A(1R,3S)-Compound E -
Explore the MedChemAI to find more analogs
References
- [1]. Boyce M, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015 May;79(5):744-55. [Content Brief]
- [2]. Takinami Y, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.Aliment Pharmacol Ther. 1997 Feb;11(1):113-20. [Content Brief]
